美通社

2024-11-28 13:43

Everest Medicines Announces NEFECON®, the World's First Approved Treatment for IgA Nephropathy, is Included in China's National Reimbursement Drug List

SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that NEFECON® has been included in the National Reimbursement Drug List ("NRDL"). The 2024 NRDL will take effect starting from January 1st, 2025.

"NEFECON®'s inclusion in the NRDL acknowledges its significant clinical value in improving patient care." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, "With approximately 5 million IgAN patients in China and over 100,000 newly diagnosed patients annually, there is a significant unmet clinical demand. We believe that with NEFECON®'s inclusion in the NRDL, more patients with IgAN in China will have access to this innovative treatment and benefit from it. Moving forward, we will proactively collaborate with the government departments for the implementation of medical insurance policies, to benefit more Chinese IgAN patients and their families."

"I am excited to see NEFECON®'s inclusion in the NRDL. IgAN is highly prevalent in China and is one of the main causes of kidney failure in young adults. Compared to European and American populations, Chinese IgAN patients experience faster disease progression, poorer prognosis, and impose a heavy burden on patients and society." Said Professor Chen Nan, Director of the Department of Nephrology at Ruijin Hospital-Shanghai Jiao Tong University School of Medicine, Level II Professor and Doctoral Supervisor at Shanghai Jiao Tong University, Tenure Professor at Ruijin Hospital-Shanghai Jiao Tong University School of Medicine, Director of the Clinical Nephrology Committee of the Chinese Medicine Education Association, "As the first and only approved etiological treatment for IgAN in China, NEFECON® has been providing benefits to IgAN patients since its approval. Under the medical insurance policies, we expect more patients with IgAN can benefit from early etiological treatment to help with disease management and embrace a better life."

Results from Phase 3 clinical study NefIgArd of the Chinese population shows that NEFECON® reduces kidney function decline by 66%, and delays disease progression to dialysis or kidney transplantation by 12.8 years. With its innovative mechanism of action and clinical benefit, NEFECON® has been recommended by multiple domestic and international treatment guidelines, further established its first-line cornerstone position in IgAN treatment.

NEFECON® has been prescribed in mainland China since May this year and has been approved in Macau, Hong Kong, Taiwan, China, South Korea and in Singapore under the trade name Nefegan®.

NEFECON® was first approved in December 2021 by the United States FDA under the trade name TARPEYO® and was in 2022 approved by the European Commission and in 2023 by the MHRA, United Kingdom under the trade name Kinpeygo®. The product is marketed in the US by Calliditas Therapeutics AB and in Europe by Calliditas' commercial partner, STADA Arzneimittel AG.

About NEFECON®

NEFECON® is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. The formulation is designed as a delayed release capsule that is enteric coated so that it remains intact until it releases budesonide to the distal ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum where the disease originates, as per the predominant pathogenesis models.

In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas Therapeutics, which gives Everest Medicines exclusive rights to develop and commercialize NEFECON® in mainland China, Hong Kong, Macau, Taiwan, China and Singapore. The agreement was extended in March 2022 to include South Korea as part of Everest Medicine's territories.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company's core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

source: Everest Medicines

《說說心理話》成人亦會專注力不足?嘉賓分享中年確診過度活躍症+自閉症過程!► 即睇

上一篇新聞︰2024-11-28 13:50  Gravity Announces Global Release of Tokyo Psychodemic

下一篇新聞︰2024-11-28 13:43  為什麼台灣是數位人才的理想之地?

人氣文章
最近7天
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
3
財政預算案2025 | 重點文字直播/Youtube直播(稍後送上懶人包)
4
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
5
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
6
高息定存 | 一周高息合集,3個月5厘之選有邊間?6個月最高3.55厘
7
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
8
高息定存 | 一周高息合集,減息預期降溫,銀行3個月最高5.68厘,6個月3.55厘
9
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
10
【FOCUS】悟空、哪吒、DeepSeek,如何啟示香港
11
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
12
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
13
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
14
高息定存 | 信銀國際12個月港元定存高達3.5厘
15
日入而息 | 習近平據報下周見科企領袖,證監會審視8券商孖展風控,大酒店轉蝕9億
16
彭博亞洲20大富裕家族,香港5大家族上榜,新地郭氏排名最高,無李嘉誠李兆基?
17
民營企業座談會 | 習近平在京出席民營企業座談會
18
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
19
AI | 追捧DeepSeek,全球對沖基金棄印度投中國
20
David Webb:因病情惡化,將有序結束個人財經網站
21
2025強積金整合獎賞一覽 轉供應商最多竟然可賺!?
22
AI | 蔡崇信確認阿里與蘋果合作,撰文談DeepSeek崛起帶來兩大啟示
23
譚仔 | 譚仔國際日資大股東溢價76%建議私有化今復牌,上市不足三年半
24
比特幣 | 亞洲時段虛擬貨幣大幅下跌,31萬人爆倉
25
港股 | 蕭猷華:恒指升勢可持續?
26
神州經脈 | 習近平:經濟政策不會變,民企大顯身手正當其時
27
美股收盤 | 美股三大指數收市報跌,道指跌近750點
28
神州經脈 | 中國減持美債,螞蟻入局具身智能,70城樓價向好
29
港股 | 蕭猷華:恒指上半年目標25000點
30
隱瞞「賣殼」欺詐罪成,詹培忠判囚34個月,詹劍崙囚37個月
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

etnet榮膺「第九屆傳媒轉型大獎」四大獎項

【限時優惠$68/月】申請etnet強化版MQ手機串流報價服務 捕捉板塊輪動,提高獲利勝算

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

2025-26年度財政預算案

貨幣攻略

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老